CN118240882A - Multi-gene deleted high-yield baculovirus expression vector Bac6.0s and application thereof - Google Patents
Multi-gene deleted high-yield baculovirus expression vector Bac6.0s and application thereof Download PDFInfo
- Publication number
- CN118240882A CN118240882A CN202410489880.7A CN202410489880A CN118240882A CN 118240882 A CN118240882 A CN 118240882A CN 202410489880 A CN202410489880 A CN 202410489880A CN 118240882 A CN118240882 A CN 118240882A
- Authority
- CN
- China
- Prior art keywords
- gene
- recombinant baculovirus
- deletion
- baculovirus vector
- baculovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701447 unidentified baculovirus Species 0.000 title claims abstract description 138
- 239000013604 expression vector Substances 0.000 title abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 194
- 230000014509 gene expression Effects 0.000 claims abstract description 65
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000012224 gene deletion Methods 0.000 claims abstract description 16
- 239000013598 vector Substances 0.000 claims description 77
- 238000012217 deletion Methods 0.000 claims description 54
- 230000037430 deletion Effects 0.000 claims description 54
- 241000700605 Viruses Species 0.000 claims description 28
- 239000003550 marker Substances 0.000 claims description 16
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims description 16
- 230000017105 transposition Effects 0.000 claims description 15
- 108700008625 Reporter Genes Proteins 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 241000219823 Medicago Species 0.000 claims description 8
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 8
- 229910052709 silver Inorganic materials 0.000 claims description 8
- 239000004332 silver Substances 0.000 claims description 8
- 210000003462 vein Anatomy 0.000 claims description 8
- 108010091086 Recombinases Proteins 0.000 claims description 7
- 102000018120 Recombinases Human genes 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 240000000220 Panda oleosa Species 0.000 claims description 6
- 235000016496 Panda oleosa Nutrition 0.000 claims description 6
- 101710172711 Structural protein Proteins 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000006801 homologous recombination Effects 0.000 claims description 4
- 238000002744 homologous recombination Methods 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 241000200174 Noctiluca Species 0.000 claims description 3
- 241000256259 Noctuidae Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000010076 replication Effects 0.000 abstract description 4
- 239000013612 plasmid Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 31
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 16
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 15
- 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 description 15
- 102000053400 human TPO Human genes 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 230000009466 transformation Effects 0.000 description 12
- 238000001890 transfection Methods 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 108700039887 Essential Genes Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000012869 ethanol precipitation Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000010367 cloning Methods 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010084455 Zeocin Proteins 0.000 description 4
- 238000013320 baculovirus expression vector system Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000055501 telomere Human genes 0.000 description 4
- 108091035539 telomere Proteins 0.000 description 4
- 210000003411 telomere Anatomy 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 244000292604 Salvia columbariae Species 0.000 description 3
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 3
- 235000001498 Salvia hispanica Nutrition 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 235000014167 chia Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 241000537219 Deltabaculovirus Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- -1 antibodies) Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 101150055869 25 gene Proteins 0.000 description 1
- 244000178606 Abies grandis Species 0.000 description 1
- 235000017894 Abies grandis Nutrition 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000256247 Spodoptera exigua Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a high-yield baculovirus expression vector Bac6.0s with multiple gene deletions and application thereof. In the invention, about 25 genes are deleted on a large scale, so that the stability of baculovirus genome is obviously improved and the expression of exogenous proteins is optimized under the condition of keeping good replication capacity, and the method can be suitable for the production of various biological products and has application prospect.
Description
Technical Field
The invention belongs to the technical field of bioengineering, and mainly relates to a high-yield baculovirus expression vector Bac6.0s with multiple gene deletions and application thereof.
Background
Baculovirus (Baculovirus) is a class of circular supercoiled double-stranded DNA viruses with envelope coating. Currently, most studied baculovirus is the alfalfa silver vein moth nuclear polyhedrosis virus (Autographa californica nucleopolyhedrovirus, acMNPV) as a baculovirus whose genome size is about 134kb, encoding 151 open reading frames in total. Simth et al in 1983 successfully expressed Human interferon-beta (IFN-beta) using baculovirus for the first time. Then, a baculovirus expression system (Baclovirus expression vector system, BEVS) for expressing a foreign protein in an insect or in a cell using a baculovirus carrying a foreign gene as an expression vector has been developed.
Although BEVS is a highly efficient eukaryotic expression system, it has its own limitations, mainly including: glycosylation problems, protein degradation problems, and genomic stability problems. Among them, the glycosylation problem has been solved to some extent by modification of the glycosylation pathway of insect cell lines.
The continuous enrichment of the gene editing means makes the BEVS technology effectively improved. In order to alleviate the problem of degradation of foreign proteins and to increase the stability of viral genes, and to increase the yield and quality of the protein of interest, expression elements of BEVS are constantly optimized, baculovirus genomes are modified a number of times, and a number of baculovirus vectors are established.
However, currently available baculovirus vectors are limited in the art, and it is difficult to comprehensively consider the excellent properties of genome stability, protein expression stability, viral substrates, viral replication and the like. Thus, there is a need for an improved field of baculovirus vectors.
Disclosure of Invention
The invention aims to provide a polygene-deleted high-yield baculovirus expression vector Bac6.0s and application thereof.
In a first aspect of the invention there is provided the use of a recombinant baculovirus vector for: (a) preparing a recombinant baculovirus; or (b) inserting an exogenous gene to express the exogenous gene; wherein the recombinant baculovirus vector is an engineered baculovirus vector, takes a nuclear polyhedrosis virus (AcMNPV) genome sequence of the Autographa californica as a basic sequence, and carries out polygene deletion (deletion) including deletion Ac15、Ac16、Ac20/21、Ac22、Ac42、Ac43、Ac44、Ac55、Ac56、Ac57、Ac58/59、Ac60、Ac61、Ac69、Ac70、Ac72、Ac84、Ac85、Ac86、Ac87、Ac88 and Ac91; deleting a gene selected from the group consisting of: ac47, ac48 and Ac49 (Bac6.0-1, reduced by 19364 bp), or Ac148, ac149 and Ac150 (Bac6.0-2, reduced by 19593 bp).
In a preferred embodiment, in (a), the recombinant baculovirus vector (bacmid) is transfected into a virus-producing cell to produce the recombinant baculovirus.
In another preferred example, in (b), a recombinant baculovirus vector (bacmid) into which a foreign gene is inserted is transfected into a virus-producing cell to produce the recombinant baculovirus, which expresses a foreign protein.
In another preferred example, the genomic sequence of the noctiluca californica nuclear polyhedrosis virus (AcMNPV) as a base sequence for constructing a baculovirus vector includes Ac1 to Ac154 genes (also referred to as Ac1 to Ac154 Open Reading Frames (ORFs)); preferably, the alfalfa silver vein moth nuclear polyhedrosis virus (AcMNPV) genomic sequence is an artificial sequence from EmBacY bacmid.
In another preferred example, homologous recombination is performed using a λred recombinase, and deletion (deletion) of a gene is performed; preferably, deletion (deletion) of the gene is performed using the lambda Red recombinase/I-SceI enzyme traceless editing system.
In another preferred embodiment, the foreign gene insertion site is an enzyme cleavage site.
In another preferred example, the foreign gene insertion site may be one or more insertion sites.
In another preferred embodiment, the elements required for expression of the foreign gene and optionally the resistance selection marker and/or reporter gene in the baculovirus vector are operatively linked.
In another aspect of the invention, there is provided a method of constructing a baculovirus vector comprising: the alfalfa silver vein moth nuclear polyhedrosis virus (AcMNPV) genome is taken as the basis for constructing a baculovirus vector, and polygene deletion (deletion) is carried out, including deletion Ac15、Ac16、Ac20/21、Ac22、Ac42、Ac43、Ac44、Ac55、Ac56、Ac57、Ac58/59、Ac60、Ac61、Ac69、Ac70、Ac72、Ac84、Ac85、Ac86、Ac87、Ac88 and Ac91, and deletion of genes selected from the following groups: ac47, ac48 and Ac49, or Ac148, ac149 and Ac150.
In another preferred embodiment, the baculovirus vector is further provided with elements required for expression of the foreign gene; preferably, the elements include (but are not limited to): promoters, replicons, transposition sites, foreign gene insertion sites (e.g., cleavage sites); optionally, the element further comprises: resistance selection markers, reporter genes.
In another preferred embodiment, the promoter comprises (but is not limited to) a ph promoter, the replicon comprises (but is not limited to) a mini-F replicon, the transposition site comprises (but is not limited to) an attTn7 transposition site, the resistance selection marker comprises (but is not limited to) a kana (Kan) resistance selection marker, and the reporter gene comprises (but is not limited to) an eYFP fluorescent gene.
In another aspect of the present invention, there is provided a recombinant baculovirus vector which is an engineered baculovirus vector based on the alfalfa silver vein moth nuclear polyhedrosis virus (AcMNPV) genomic sequence and which performs multiple gene deletion (deletion) including deletion Ac15、Ac16、Ac20/21、Ac22、Ac42、Ac43、Ac44、Ac55、Ac56、Ac57、Ac58/59、Ac60、Ac61、Ac69、Ac70、Ac72、Ac84、Ac85、Ac86、Ac87、Ac88 and Ac91, and deletion of a gene selected from the group consisting of: ac47, ac48 and Ac49 (Bac6.0-1, reduced by 19364 bp), or Ac148, ac149 and Ac150 (Bac6.0-2, reduced by 19593 bp).
In another preferred embodiment, the recombinant baculovirus vector further comprises elements required for expression of a foreign gene; preferably, the elements include (but are not limited to): promoters, replicators, transposition sites, foreign gene insertion sites; optionally, the element further comprises: resistance selection markers, reporter genes.
In another preferred embodiment, the promoter comprises (but is not limited to) a ph promoter, the replicon comprises (but is not limited to) a mini-F replicon, the transposition site comprises (but is not limited to) an attTn7 transposition site, the resistance selection marker comprises (but is not limited to) a kana (Kan) resistance selection marker, and the reporter gene comprises (but is not limited to) an eYFP fluorescent gene.
In another preferred embodiment, the alfalfa silver vein moth nuclear polyhedrosis virus (AcMNPV) genomic sequence is an artificial sequence from EmBacY bacmid.
In another aspect of the invention there is provided a recombinant baculovirus obtained from the recombinant baculovirus vector packaging as described in any one of the preceding; or it is obtained by packaging the recombinant baculovirus vector of any one of the foregoing inserted with a foreign gene, which is capable of expressing a foreign protein.
In another aspect of the invention, there is provided a method of preparing a recombinant baculovirus comprising: (A) Preparing a recombinant baculovirus vector as described in any one of the preceding; (B) Transfecting the recombinant baculovirus vector of (A) into a virus-producing cell, thereby packaging to obtain the recombinant baculovirus.
In another preferred example, a recombinant baculovirus vector (bacmid) into which a foreign gene is inserted is transfected into a virus-producing cell to produce the recombinant baculovirus, which expresses a foreign protein.
In another aspect of the invention there is provided the use of said recombinant baculovirus for: expressing the exogenous gene to obtain an exogenous protein; preferably, the exogenous protein includes: immunogenic proteins, pharmaceutically active proteins, diagnostically active proteins, structural proteins, enzymes, fusion peptides, reporter proteins.
In another aspect of the invention, there is provided a kit comprising: the recombinant baculovirus vector of any one of the preceding claims, or the recombinant baculovirus; preferably, virus-producing cells are also included.
Other aspects of the invention will be apparent to those skilled in the art in view of the disclosure herein.
Drawings
FIG. 1, the present invention provides the expression of hTPO protein from baculovirus expression vectors deleted for 7 individual nonessential genes, ac15KO, ac47KO, ac61KO, ac69KO, ac85KO, ac91KO, ac149KO, using WT as a control, where individual deletion of these nonessential genes did not raise the expression level of the foreign protein.
FIG. 2, the present invention provides schematic representation of knock-out strategy for multiple gene deletions on baculovirus vectors.
FIG. 3, the present invention provides fluorescent particle figures of two polygene deletion baculovirus vectors Bac6.0-1 and Bac6.0-2 after transfection of Sf9 cells, and the Bac6.0-1 and Bac6.0-2 have normal virus infection diffusion capacity and expression capacity of ph promoter by adopting a WT control.
FIG. 4 shows that Bac6.0-1 and Bac6.0-2 polygene deletion baculovirus vectors provided by the invention are used for expressing hTPO, western blot detection is carried out after sampling, and the results show that the expression level of exogenous proteins is obviously improved by Bac6.0-1 and Bac6.0-2, and the expression level of hTPO is respectively improved by 2.3 times and 2.6 times through gray scale scanning analysis.
FIG. 5, acMNPV gene distribution and region division map.
Detailed Description
In the optimization research on baculovirus expression vectors, the inventor identifies a series of genes on the AcMNPV as nonessential genes for baculovirus infection diffusion in the early analysis work, but deletion of a single gene has the priority of deleted bases on one hand and has no obvious improvement on the expression level of exogenous proteins on the other hand. In order to improve the practicability and performance of the baculovirus expression vector (comprising improving the virus infection diffusion capability and improving the expression of exogenous genes), the inventor further optimizes the vector, and by preparing a large number of combined gene deletion vectors, the recombinant baculovirus expression vector (Bac6.0s: bac6.0-1 and Bac6.0-2) with stable and simple genes, high virus infection diffusion capability and high efficient expression of exogenous genes is obtained through optimization.
Terminology
As used herein, the term "exogenous" or "heterologous" refers to a relationship between two or more nucleic acid or protein sequences from different sources, or a relationship between a nucleic acid from different sources and a host cell. For example, if the combination of nucleic acid and host cell is not normally naturally occurring, the nucleic acid is heterologous to the host cell. The particular sequence is "exogenous" to the cell or organism into which it is inserted.
As used herein, the term "expression cassette" refers to a gene expression system comprising all the necessary elements necessary for expression of a gene of interest, typically comprising the following elements: a promoter, a target gene sequence, and a terminator; in addition, signal peptide coding sequences and the like can be optionally included. These elements are operatively connected.
As used herein, the term "element" refers to a series of functional nucleic acid sequences useful for the expression of proteins. The sequences of the "elements" may be those provided in the present invention, and include variants thereof, as long as the variants substantially retain the function of the "elements" obtained by inserting or deleting some bases (e.g., 1 to 50bp; preferably 1 to 30bp, more preferably 1 to 20bp, still more preferably 1 to 10 bp), or performing random or site-directed mutation, etc.
As used herein, the term "operably linked" or "operably linked" refers to a functional spatial arrangement of two or more nucleic acid regions or nucleic acid sequences. For example: the promoter region is placed in a specific position relative to the nucleic acid sequence of the gene of interest such that transcription of the nucleic acid sequence is directed by the promoter region, whereby the promoter region is "operably linked" to the nucleic acid sequence.
As used herein, an "effective amount" or "effective dose" refers to that amount which is functional or active in and acceptable to a human and/or animal as used herein.
As used herein, a "pharmaceutically acceptable" ingredient is a substance that is suitable for use in humans and/or mammals without undue adverse side effects (such as toxicity, irritation, and allergic response), commensurate with a reasonable benefit/risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.
As used herein, "comprising" means that the various ingredients can be applied together in a mixture or composition of the invention. Thus, the terms "consisting essentially of and" consisting of are encompassed by the term "containing.
Carrier body
There are many uncertain factors in the modification of baculovirus, the genome of which is known, but the genes of which are numerous and complex, and particularly how to actually improve the expression efficiency of the exogenous genes on the basis of maintaining the stability of the genome and high virus infection spreading capability remains a bottleneck in the field. Although the present inventors analyzed a series of genes of interest in previous studies, there was no significant effect on how to increase the expression of exogenous genes. The related research of combining deletion such as the gene of the invention and exploring multi-gene deletion on baculovirus vectors on baculovirus expression systems has not been reported at present. In the invention, by deleting genes irrelevant to baculovirus packaging replication production, the size of baculovirus genome is reduced to improve the stability of baculovirus genome and optimize the expression of exogenous proteins, a group of baculovirus expression vectors is provided, and the invention can adapt to the production of various biological products and has application prospect.
The invention aims at respectively carrying out superposition deletion on each gene on the AcMNPV, constructing a series of multi-gene deleted baculovirus expression vectors and optimizing a baculovirus system. In the specific embodiment of the invention, two high-yield baculovirus expression vectors with multiple gene deletions are prepared, the inventor refers to the vectors as Bac6.0-1 and Bac6.0-2, the genome of the vectors is relatively simple, but the vectors have good Virus infection diffusion capability, the expression level of foreign proteins is remarkably improved, and the vectors have wide application prospects in the biological product industry fields of subunit vaccines, virus LIKE PARTICLES (VLPs) vaccines, recombinant adeno-associated Virus (rAAV) vaccines and the like.
In the early stage of research, the inventor firstly tries a modification scheme of single gene deletion, uses baculovirus expression vectors deleted by various single genes (Ac 15KO, ac47KO, ac61KO, ac69KO, ac85KO, ac91KO, ac149KO and the like) to express recombinant human thyroid peroxidase (Human thyroid peroxidase, hTPO), uses a wild type baculovirus expression vector EmBacY (WT), and does not increase the expression level of exogenous proteins through Western blot detection.
Subsequently, the inventors, facing complex viral genomes, roughly divided their genes into 10 regions based on AcMNPV genome, performed different superposition combinations, successively reduced AcMNPV genome, and constructed a series of polygene deleted baculovirus vectors by iterative deletion method. In a preferred embodiment, ac1-7 is designated as region II, ac15-Ac22 is designated as region III, ac27-33 is designated as region IV, ac42-44 is designated as region I, ac47-49 is designated as region V, ac55-61 is designated as region VI, ac69-72 is designated as VII, ac84-91 is designated as region VIII, ac105-124 is designated as region IX, ac148-150 is designated as region X, and the 10 regions above are each deleted by superposition. Information on the Ac1-154 gene has been disclosed in NCBI (GeneBank: KM 667940.1).
,Ac15、Ac16、Ac20/21、Ac22、Ac42、Ac43、Ac44、Ac55、Ac56、Ac57、Ac58/59、Ac60、Ac61、Ac69、Ac70、Ac72、Ac84、Ac85、Ac86、Ac87、Ac88、Ac91、Ac47、Ac48 And Ac49 in Bac6.0-1 of the present invention were deleted. I.e., up to 25 deleted genes.
,Ac15、Ac16、Ac20/21、Ac22、Ac42、Ac43、Ac44、Ac55、Ac56、Ac57、Ac58/59、Ac60、Ac61、Ac69、Ac70、Ac72、Ac84、Ac85、Ac86、Ac87、Ac88、Ac91、Ac148、Ac149 And Ac150 in Bac6.0-2 of the present invention were deleted. I.e., up to 25 deleted genes.
Bac6.0-1, bac 6.0-two baculovirus vectors reduce baculovirus genome by about 19kb, so that the expression level of foreign proteins is improved by 2.3 and 2.6 times respectively, and the method has wide application prospect in the biological product industry fields of subunit vaccines, virus LIKE PARTICLES (VLPs) vaccines, recombinant adeno-associated Virus (rAAV) vaccines and the like, and the baculovirus system is optimized to meet the diversified production requirements of different biological products.
In the early work of the invention, recombinant human thyroid peroxidase (Human thyroid peroxidase, hTPO) was expressed by using baculovirus expression vectors deleted in total of 7 single nonessential genes of Ac15KO, ac47KO, ac61KO, ac69KO, ac85KO, ac91KO and Ac149KO, and the expression level of exogenous proteins was not increased as detected by Western blot with wild type baculovirus expression vector EmBacY (WT).
After intensive research analysis, the constructed multi-gene deleted baculovirus expression vectors Bac6.0-1 and Bac6.0-2 are obviously improved. Taking WT as a control, the inventor respectively performs transfection experiments of Sf9 cells to prepare P1 generation recombinant viruses, and obtains the P1 generation recombinant viruses to re-infect the Sf9 cells, and performs fluorescent particle condition observation in the infection and transfection processes. Two multi-gene deleted baculovirus expression vectors of Bac6.0-1 and Bac6.0-2 are identified to have normal virus replication infection capacity and ph promoter expression capacity. Bac6.0-1 and Bac6.0-2 both reduced baculovirus genome by about 19kb and significantly increased expression levels of foreign proteins.
In the embodiment of the invention, DH10Bac strain containing EmBacY stem grains is taken as a genetic operation object for convenient observation of transfection infection, emBacY stem grains are artificially modified AcMNPV genome, mini-F replicons, kana (Kan) resistance screening markers and attTn7 transposition sites are integrated at the polyhedron sites, and chiA, v-cath gene sites are replaced by eYFP fluorescent markers expressed by a ph promoter, so that visualization of the transfection infection process is ensured.
In the present invention, ac15-Ac22 is designated as region III, ac42-44 is designated as region I, ac47-49 is designated as region V, ac55-61 is designated as region VI, ac69-72 is designated as VII, ac85-91 is designated as region VIII, ac148-150 is designated as region X, and the above regions are deleted by superposition.
In the embodiment of the invention, the gene deletion is realized through a lambda red/I-SceI traceless marker system, and the method mainly comprises two steps:
(1) The resistance gene replaces the target region. Amplifying a spectinomycin (Spec) resistance screening marker expression cassette with I-SceI enzyme cleavage recognition sites at two ends by using a linear targeting primer carrying 50bp homology arms at the upstream and downstream of a target region, performing ethanol precipitation purification on the obtained PCR product, then electrically transforming the PCR product into a DH10Bac strain containing EmBacY rod grains, and obtaining an intermediate deletion strain of a resistance gene replacement target region through lambda red homologous recombination and Spec resistance screening.
(2) Traceless substitution of the resistance gene. To meet the overlapping deletions of the regions on the AcMNPV genome, a Spec-resistant gene expression cassette of the middle deleted strain was subjected to traceless substitution. First, it is necessary to construct different make-up Donor plasmids, and the construction of Donor plasmids is divided into two cases depending on whether or not the target region contains an essential gene. When all of the target region is a non-essential gene, such as region I, only about 500bp of the sequence at the upstream and downstream of the target region I needs to be connected to pKSI-1 plasmids containing I-SceI recognition sites at the two ends of the MCS to construct a make-up Donor plasmid; when the target region species contains an essential gene, e.g., region II, it is necessary to construct a make-up Donor plasmid by adding an essential gene sequence between the 500bp homology arms upstream and downstream of region II. And then the mending Donor plasmid is transformed into an intermediate deletion strain, IPTG induces and expresses I-SceI enzyme, homologous recombination is carried out under the assistance of a lambda red system recombinase, the traceless replacement of Spec resistance genes is realized, and finally two multi-gene deleted baculovirus expression vectors, namely Bac6.0-1 and Bac6.0-2, are obtained.
To investigate the viral replication and infection capacities of Bac6.0-1 and Bac6.0-2, P1 generation recombinant viruses were prepared by performing transfection experiments of Sf9 cells with wild-type EmBacY (WT) as a control, and P2 generation viruses were prepared by re-infecting Sf9 cells from P1 generation viral supernatants after 96 hours. Bac6.0-1 and Bac6.0-2 were tested for their ability to replicate as the WT virus infection.
The present invention allows for the reduction of genes, allowing for the accommodation of a greater length, variety of exogenous genes, which may be one or more. The foreign gene may be single-copy or multi-copy.
As a preferred embodiment of the invention, the vector further comprises an operably linked element or gene selected from the group consisting of: elements required for expressing a foreign gene (gene of interest); preferably, the elements include, but are not limited to: promoters, replicons, transposition sites, foreign gene insertion sites (e.g., cleavage sites); optionally, the element further comprises: resistance selection markers, reporter genes. It will be appreciated that the design of the reporter gene, cleavage site etc. elements is sometimes intended to provide a convenient way of observation or detection when studied, but is not necessary when the recombinant baculovirus vector or recombinant baculovirus of the invention is used in the clinical pharmaceutical field; or may be replaced with a gene capable of expressing a foreign protein having pharmaceutical activity (protein of interest) at the position of the reporter gene.
The expression vector will typically also contain an origin of replication and/or other marker genes, etc. According to the teachings of the present invention, methods well known to those skilled in the art can be used to construct the expression vectors required for the present invention. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombinant techniques, and the like. The DNA sequence may be operably linked to an appropriate promoter in an expression vector to direct mRNA synthesis. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator. Furthermore, the expression vector preferably comprises one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells.
The expression vector of the invention can be inserted with an expression cassette of an exogenous gene, thereby expressing the exogenous protein of interest. The baculovirus expression vector can be used as an expression vector platform, is suitable for expressing various exogenous proteins, and is not particularly limited. As some alternative embodiments, the exogenous proteins include (but are not limited to): immunogenic proteins, pharmaceutically active proteins (e.g., antibodies), diagnostically active proteins (e.g., antibodies), structural proteins, enzymes, fusion peptides, and reporter proteins. The foreign protein may be a single or two or more, so long as the length of the encoding gene is within the packaging capacity which the baculovirus can accommodate.
In the expression vector of the present invention, the insertion position of the foreign gene expression cassette may not be unique, and may be any suitable position on the vector.
The elements of the expression vectors of the invention are operably linked to facilitate packaging of the virus or efficient expression of the foreign protein.
In addition to engineering against wild-type to construct the novel baculovirus vectors of the invention, synthetic biology-based techniques can also be used to construct the novel baculovirus vectors of the invention. In contrast to the research direction of traditional biology, synthetic biology is to build parts from the most basic elements step by step, design and modify genetic materials in the process, and finally obtain ideal new-born objects. However, it should be understood that in addition to the synthetic biological techniques, other methods of constructing the baculovirus vectors of the present invention are also contemplated by the present invention after the technical solutions of the present invention are obtained.
The invention provides a new method for constructing a novel baculovirus vector, is beneficial to expanding the application of the baculovirus vector, has more flexible length of the exogenous gene which can be accommodated by the baculovirus vector, and provides a foundation for expressing more kinds of proteins by applying the baculovirus vector.
The vector of the invention can be applied to various basic researches and clinical applications, such as being used as an expression vector of various genes, expressing exogenous proteins, and also being applied to drug screening, vaccine research and development, gene therapy and the like. Has the characteristics of safety, high efficiency and stability.
The viral plasmids exemplified in the examples of the present invention use a specific promoter (ph promoter). It will be appreciated that other types of promoters are also useful. Such as the early promoter p6.9, p10 or vp39 promoter. Other early promoters are also for example 39K or gp64. Promoters pSeL from asparagus caterpillar nuclear polyhedrosis virus (Spodoptera exigua multicapsid nucleopolyhedrovirus, seMNPV) are also useful. A promoter named pB2 from High Five cells may also be used. Very early promoter OpIE from the yellow fir moth nuclear polyhedrosis virus (Orygia pseudotsugata multicapsid nucleopolyhedrovirus, opMNPV) can also be used. The Ac46 promoter has higher activity, can be used in combination with the ph or p10 promoter, and has a superposition effect on the expression of a target gene so as to further improve the expression level of the exogenous protein. Enhancers are DNA elements that increase the expression level of a certain gene and can be used in combination with a promoter to increase its activity. hr1 can increase the expression level of exogenous proteins in both Sf21 and High Five cells. In addition to promoters, other operational elements on the engineered baculovirus vectors of the invention may be replaced with other homofunctional elements, and are included within the scope of the invention.
Baculovirus
After the baculovirus expression vector is obtained, the baculovirus expression vector is transfected into virus-producing cells to reproduce viruses. After a period of time following transfection, the virus may be harvested. The virus-producing cells may be any of a variety of cells known in the art capable of propagating baculoviruses, preferably Sf9 cells and the like.
As a preferred mode of the invention, the harvested virus may be repeatedly infected with virus-producing cells and passaged continuously. The determination of viral titer (TCID 50) can be performed according to methods conventional in the art. The recombinant baculovirus obtained is also encompassed by the present invention.
The baculovirus obtained by expression of the baculovirus vector can generate high-titer viruses in a short time; the exogenous gene loading is high. According to the results of the present inventors, the exogenous gene loading amount was high.
Compositions, kits or kits
The invention also provides a composition comprising an effective amount of said baculovirus, and a pharmaceutically acceptable carrier. Preferably, the baculovirus expresses a foreign protein of interest. For example, the exogenous proteins include, but are not limited to: immunogenic proteins, pharmaceutically active proteins (e.g., antibodies), diagnostically active proteins (e.g., antibodies), structural proteins, enzymes, fusion peptides.
Typically, the baculovirus is formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is typically about 5-8, preferably about 6-8.
Based on the new findings of the present invention, a kit/kit is also provided comprising said baculovirus expression vector or said baculovirus. The kit/kit may also include virus-producing cells (e.g., sf9 cells), culture medium, and the like.
In addition, the kit/kit may further comprise instructions for use of the baculovirus following the expression method.
The invention provides diversified choices for the production of exogenous recombinant proteins, vaccines, gene therapy vectors and other biological products.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedures, which are not specifically noted in the examples below, are generally carried out according to conventional conditions such as those described in J.Sam Brookfield et al, molecular cloning guidelines, third edition, scientific Press, or according to the manufacturer's recommendations.
Experimental methods and materials
The DH10Bac strain containing EmBacY rod grains is derived from the national center of protein science (Shanghai), and three plasmids, namely pREDTKI, pMDISI and pKSI-1, in a lambda red/I-SceI traceless editing system are derived from the Proc of the university of North China, namely the Proc of biological engineering; the resistance of both pREDTKI and pKSI-1 plasmids was replaced, with pREDTKI replaced by Kan resistance with hygromycin (Hph) resistance and pKSI-1 replaced by ampicillin (Amp) resistance with bleomycin (Zeocin) resistance. Unless otherwise stated, the subsequent examples were run with plasmid after resistance change.
Example 1 AcMNPV Gene distribution, region division and traceless deletion of Gene regions
1. AcMNPV gene distribution and region division
Based on the alfalfa silver vein moth nuclear polyhedrosis virus (AcMNPV) genome (GeneBank: KM 667940.1), the inventor performs analysis and research on nonessential genes, and performs various superposition deletion analysis on the basis so as to construct a multi-gene deletion baculovirus expression vector with a simplified sequence.
In order to facilitate the observation of transfection and infection, a DH10Bac strain (derived from the national center for protein science (Shanghai)) containing EmBacY stem grains was used as a genetic manipulation object, emBacY stem grains were artificially modified AcMNPV genome, and the following modifications were made on the basis of the AcMNPV genome: the polyhedron locus integrates a mini-F replicon, a kana (Kan) resistance screening marker and an attTn7 transposition locus, and two gene loci of the chiA and v-cath are replaced by coding genes of an eYFP fluorescent marker expressed by a ph promoter, so that the visualization of the transfection and infection process is ensured; two sites, chiA, v-cath, also introduce a loxp site and Amp resistance.
In order to perform sequence reduction optimization, the inventor divides genes on the AcMNPV into 10 areas, performs different superposition combinations, continuously reduces the AcMNPV genome, and constructs a series of polygene deletion baculovirus vectors by adopting an iterative deletion method. Ac1-7 was designated as region II, ac15-Ac22 was designated as region III, ac27-33 was designated as region IV, ac42-44 was designated as region I, ac47-49 was designated as region V, ac55-61 was designated as region VI, ac69-72 was designated as VII, ac84-91 was designated as region VIII, ac105-124 was designated as region IX, ac148-150 was designated as region X, and the above 10 regions were each deleted by superposition. AcMNPV gene distribution and regional division map are shown in figure 5.
Gene deletion was achieved by the lambda red/I-SceI traceless marker system.
The multiple gene deletions included Spec resistance gene replacement target region and Spec resistance gene traceless elimination, deletion strategies see Step1 and Step2 of fig. 2, with primers shown in table 1.
TABLE 1 primers used in the present invention
Wherein the underlined sequence is a primer sequence that binds to the resistance gene template plasmid pDMISI.
Construction of Bac6.0-1 and Bac6.0-2
2.1 Deletion of region I
First DH10Bac calcium transfer competence containing EmBacY rod grains is prepared, pREDTKI plasmid encoding lambda red recombinase and I-SceI enzyme is transformed, screening is carried out on Kan+Hph+Tet resistance plates, positive monoclonal preparation of electric transfer competence is reserved.
The Spec resistance gene expression cassette with 50bp homology arms at the upstream and downstream of Ac42-44 and I-SceI cleavage recognition sites was amplified by PCR using the primers Spec-Ac42-F and Spec-Ac44-R and pMDISI plasmid as a template, and subjected to fragment recovery using a DNA gel recovery kit, ethanol precipitation purification and electrotransformation into pREDTKI positive DH10Bac competence. With the help of lambda red recombinase expressed by L-arabinose induction, a Spec resistance expression cassette recombination region I is screened on a Kan+Hph+Tet+spec resistance plate to obtain positive monoclonal, PCR verification and sequencing is carried out by adopting primers Ac42KO-F and Ac44KO-R to obtain a deletion strain of which the region I is replaced by a Spec resistance gene, named Ac42-44KO, and calcium transfer competence is prepared for standby.
The analysis shows that the region I is all non-essential genes, and the supplementary Donor plasmid is constructed as follows: amplifying the gene of about 500bp at the upstream of Ac42 by using a primer Ac42-D1/D2 and EmBacY rods as templates, and amplifying the gene of about 500bp at the downstream of Ac44 by using a primer Ac44-D1/D2 and EmBacY rods as templates; meanwhile, a primer p-4-F/R is used, and pKSI-1 plasmid is used as a template to obtain the pKSI-1 linearization vector.
The pKSI-1 linearization vector, up sequence and down sequence were ligated using a seamless cloning kit, transformed into pFastT competent, constructed as a make-up plasmid Donor-1, coated on Zeocin resistance plates, and after PCR-verified sequencing using primer Donor-F/R, the make-up plasmid Donor-1 was transformed into Ac42-44KO, coated on Kan+Hph+Tet+spec+Zeocin resistance plates for selection. The positive monoclonal is inoculated in 1ml Kan+Hph+Tet+Spec+Zeocin liquid culture medium and cultured overnight at 30 ℃ to be the primary bacterium. The primary bacteria are inoculated in 4ml Kan+Hph+Tet liquid culture medium according to 1% inoculation amount, 10mM L-arabinose is added at the same time, 20mM IPTG is added when the temperature is 30 ℃ and the OD is approximately equal to 0.2-0.3, and the secondary bacteria are obtained after overnight culture. The secondary bacteria are inoculated in 4ml Kan+Hph+Tet liquid culture medium according to 1% inoculation amount, 10mM L-arabinose and 20mM IPTG are added at the same time, after the secondary bacteria are cultured overnight at 30 ℃, the secondary bacteria are diluted to 10 -3-10-4 and coated on Kan+Hph+Tet resistance plates, the secondary bacteria are cultured overnight at 30 ℃, and the monoclonal bacteria are selected and subjected to PCR verification by adopting Ac42-44-F/R, so that three gene-trace-free deleted pole grains of Ac42, ac43 and Ac44 in the region I are obtained and are named as Bac1.0.
2.2 Overlapping deletions of region VI on Bac1.0
The method of operation is similar to the Bac1.0 construction.
Amplifying a Spec resistance expression cassette by using primers Spec-Ac55-F and Spec-Ac61-R, performing ethanol precipitation purification on a PCR product, converting into Bac1.0 electrotransformation competence, performing PCR verification sequencing by using primers Ac55KO-F and Ac61KO-R to obtain a positive monoclonal with the region VI replaced by a Spec resistance gene, named Ac55-61KO, and preparing the calcium transformation competence for later use.
Through analysis, the region VI is all nonessential genes, a primer Ac55-D1/D2 is adopted, emBacY rod grains are used as templates, an up sequence is used for amplifying about 500bp genes on the upstream of Ac55, a primer Ac61-D1/D2 is used as templates, a EmBacY rod grains are used as templates, and a down sequence is used for amplifying about 500bp genes on the downstream of Ac61 genes; meanwhile, a primer p-6-F/R and pKSI-1 plasmid are used as templates to obtain a pKSI-1 linearization vector, a seamless cloning kit is used for connection transformation, and a compensation plasmid Donor-6 is constructed.
The anaplerotic plasmid Donor-6 was transformed into Ac55-61KO to effect traceless replacement of the Spec resistance expression cassette, resulting in a bac2.0-5 with overlapping deletions of region I and region VI.
2.3 Overlapping deletions of region VII on Bac2.0-5
The method of operation is similar to the Bac1.0 construction.
Amplifying a Spec resistance expression cassette by using primers Spec-Ac69-F and Spec-Ac72-R, performing ethanol precipitation purification on a PCR product, converting into Bac2.0-5 electrotransformation competence, performing PCR verification sequencing by using primers Ac69KO-F and Ac72KO-R to obtain a positive monoclonal with a region VII replaced by a Spec resistance gene, named Ac69-72KO, and preparing the calcium transformation competence for later use.
As a result of analysis, region VII contains, in addition to three nonessential genes Ac69, ac70 and Ac72, an essential gene Ac71, so that the elimination of the Spec-resistant fragment requires a back-filling of Ac 71. The make-up plasmid was constructed as follows: amplifying the gene of about 500bp upstream of Ac69 by using a primer Ac69-D1/D2 and EmBacY rod grains as templates to obtain an up sequence; amplifying the Ac71 sequence by using a primer Ac71-D1/D2 and EmBacY rod grains as templates; amplifying a gene about 500bp downstream of Ac72 by using a primer Ac72-D1/D2 and EmBacY rod grains as templates to obtain a down sequence; meanwhile, using pKSI-1 plasmid as a template, using a primer p-7-F/R to obtain a pKSI-1 linearization vector, and performing seamless cloning, connection and transformation to obtain a compensation plasmid Donor-7.
Donor-7 converts Ac69-72KO to realize traceless elimination of the Spec resistance expression cassette and Ac71 gene complementation, and a bac3.0-4 with overlapping deletion of region I, region VI and region VII is obtained.
2.4 Overlapping deletions of region III on Bac3.0-4
The method of operation is similar to the Bac1.0 construction.
The Spec resistance expression cassette is amplified by using the primers Spec-Ac15-F and Spec-Ac22-R, and the PCR product is subjected to ethanol precipitation and purification to convert Bac3.0-4 electrotransformation competence, so that a positive monoclonal with the region III replaced by the Spec resistance gene is obtained, named Ac15-22KO, and the calcium transformation competence is prepared for standby.
As a result of analysis, region III contained the essential genes Ac17, ac18 and Ac19 in addition to the five nonessential genes Ac15, ac16, ac20/21 and Ac22, and thus, the elimination of the Spec resistance fragment was accompanied by the need for back-filling of these three essential genes.
The make-up plasmid was constructed as follows: amplifying the gene of about 500bp upstream of Ac15 by using a primer Ac15-D1/D2 and EmBacY rod grains as templates to obtain an up sequence; amplifying the Ac17-19 sequence by using the primers Ac17-D1 and Ac19-D2 and EmBacY rod grains as templates; amplifying the about 500bp gene downstream of Ac22 by using a primer Ac22-D1/D2 and EmBacY rod grains as templates to obtain a down sequence; meanwhile, using pKSI-1 plasmid as a template, using a primer p-3-F/R to obtain a pKSI-1 linearization vector, and performing seamless cloning, connection and transformation to obtain a compensation plasmid Donor-3.
Donor-3 converts Ac15-22KO to achieve traceless elimination of the Spec resistance expression cassette and Ac17-19 gene complementation to obtain a bac4.0-1 with overlapping deletions of region I, region III, region VI and region VII.
2.5 Overlapping deletions of region VIII on Bac4.0-1
The method of operation is similar to the Bac1.0 construction.
Amplifying a Spec resistance expression cassette by using primers Spec-Ac84-F and Spec-Ac91-R, performing ethanol precipitation purification on a PCR product, converting into Bac4.0-1 electrotransformation competence, performing PCR verification sequencing by using primers Ac84KO-F and Ac91KO-R to obtain a positive monoclonal with a region VIII replaced by a Spec resistance gene, named Ac84-91KO, and preparing the calcium transformation competence for later use.
According to analysis, region VIII contains two essential genes Ac89 and Ac90 in addition to the six nonessential genes Ac84, ac85, ac86, ac87, ac88 and Ac91, so that the elimination of the Spec resistance fragment requires the back-filling of both essential genes Ac89 and Ac 90. The make-up plasmid was constructed as follows: amplifying the gene of about 800bp upstream of Ac84 by using a primer Ac84-D1/D2 and EmBacY rod grains as templates to obtain an up sequence; amplifying the Ac89-90 sequence by using the primers Ac89-D1 and Ac90-D2 and EmBacY rod grains as templates; amplifying a gene about 500bp downstream of Ac91 by using a primer Ac91-D1/D2 and EmBacY rod grains as templates to obtain a down sequence; meanwhile, using pKSI-1 plasmid as a template, using a primer p-8-F/R to obtain a pKSI-1 linearization vector, and performing seamless cloning, connection and transformation to obtain a compensation plasmid Donor-8.
Donor-8 converts Ac84-91KO to achieve traceless elimination of the Spec resistance expression cassette and Ac89-90 gene complementation to obtain a bac5.0-2 with overlapping deletions of region I, region III, region VI, region VII and region VIII.
2.6 Overlapping deletions of region V on Bac5.0-2
The method of operation is similar to the Bac1.0 construction.
The Spec resistance expression cassette is amplified by using primers Spec-Ac47-F and Spec-Ac49-R, bac5.0-2 electrotransformation competence is transformed after ethanol precipitation and purification of PCR products, PCR verification sequencing is performed by using primers Ac47KO-F and Ac49KO-R, positive monoclonal with the region V replaced by the Spec resistance gene is obtained, named Ac47-49KO, and calcium transformation competence is prepared for standby.
The region V is all nonessential genes, a primer Ac47-D1/D2 is adopted, emBacY telomeres are used as templates, an up sequence is used for amplifying about 500bp genes on the upstream of Ac47, a primer Ac49-D1/D2 is used as templates, emBacY telomeres are used as templates, and a down sequence is used for amplifying about 500bp genes on the downstream of Ac49 genes; meanwhile, a primer p-5-F/R and pKSI-1 plasmid are used as templates to obtain a pKSI-1 linearization vector, a seamless cloning kit is used for connection transformation, and a compensation plasmid Donor-5 is constructed. The anaplerotic plasmid Donor-5 was transformed into Ac47-49KO,
Traceless substitution of the Spec-resistant expression cassette was achieved, resulting in a stack of deleted bac, designated bac6.0-1, for region I, region III, region V, region VI, region VII and region VIII.
2.7 Overlapping deletions of region X on Bac5.0-2
The method of operation is similar to the Bac1.0 construction.
The Spec resistance expression cassette is amplified by using primers Spec-Ac148-F and Spec-Ac150-R, bac5.0-2 electrotransformation competence is transformed after ethanol precipitation and purification of PCR products, PCR verification sequencing is carried out by using primers Ac148KO-F and Ac150KO-R, positive monoclonal with the region X replaced by the Spec resistance gene is obtained, named Ac148-150KO, and calcium transformation competence is prepared for standby.
The region X is all nonessential genes, a primer Ac148-D1/D2 is adopted, emBacY telomeres are used as templates, an up sequence is used for amplifying about 500bp genes at the upstream of the Ac148, a primer Ac150-D1/D2 is used as templates, a EmBacY telomeres are used as templates, and a down sequence is used for amplifying about 500bp genes at the downstream of the Ac150 genes; meanwhile, a primer p-10-F/R and pKSI-1 plasmid are used as templates to obtain a pKSI-1 linearization vector, a seamless cloning kit is used for connection transformation, and a compensation plasmid Donor-10 is constructed. The make-up plasmid Donor-10 was transformed into Ac148-150KO to effect traceless replacement of the Spec resistance expression cassette, resulting in a stack of deleted bac, designated bac6.0-2, for region I, region III, region VI, region VII, region VIII and region X.
Summary
Through the above operation, a plurality of modified plasmids are obtained,
The deletion of fragments in each plasmid is shown in Table 2.
TABLE 2
Example 2 transfection infection experiments with Sf9 cells
In order to explore the influence of two polygene deletion baculovirus vectors of Bac6.0-1 and Bac6.0-2 on baculovirus infection diffusion capacity and ph promoter expression capacity, bac6.0-1 and Bac6.0-2 were subjected to bacmid extraction by using NucleoBond Xtra Midi kit, sf9 cells were transfected with wild EmBacY bacmid according to Bac-to-Bac manual, and P1 generation viruses were harvested after 96 hours.
Reinfection of fresh sf9 cells with the appropriate amount of P1 generation virus was performed and P2 generation virus was harvested 96h later.
Fluorescent observations were made during transfection and infection, with each fluorescent particle case shown in FIG. 3.
Example 3 protein expression level determination
To investigate the effect of different baculovirus expression vectors on the expression level of foreign proteins, recombinant human thyroid peroxidase (Human thyroid peroxidase, hTPO) (GenBank: NP-000538.3) was expressed on baculovirus expression vectors (Table 3) with 7 single gene deletions of Ac15KO, ac47KO, ac61KO, ac69KO, ac85KO, ac91KO, ac149KO, respectively, and the foreign gene was inserted into position atttn.
TABLE 3 Table 3
After extracting the bacmid, preparing P3 generation recombinant baculovirus by taking a wild type baculovirus expression vector EmBacY (WT) as a control, carrying out titer measurement, carrying out Sf9 cell shake flask infection according to MOI=1, and sampling after 96h infection for Western blot detection.
The results showed that Ac15KO, ac47KO, ac61KO, ac69KO, ac85KO, ac91KO, ac149KO were used to express the foreign proteins, respectively, and that the expression levels of the foreign proteins were not increased and some decreased as compared with the wild type, as shown in fig. 1.
2. Multiple gene deletion
The human thyroid peroxidase (hTPO) gene is transposed in Bac6.0-1 and Bac6.0-2 multi-gene deletion baculovirus expression vectors, and the exogenous gene is inserted into atttn sites.
After extracting the bacmid, preparing the P3 generation recombinant baculovirus by taking the wild bacmid as a control, carrying out titer measurement, carrying out Sf9 cell shake flask infection according to MOI=1, and sampling after 96h infection for Western blot detection, as shown in fig. 4.
From the above experimental results, the deletion of a single unnecessary gene does not promote the expression of foreign proteins, while two 25 gene deleted baculovirus vectors Bac6.0-1 and Bac6.0-2 constructed by the invention have about 19kb reduced baculovirus genome, and have the normal infection replication and proliferation capability of viruses and the expression capability of a ph promoter. Gray scale scanning showed 2.3 and 2.6 fold increases in hTPO expression levels, respectively (table 4).
TABLE 4 Table 4
Therefore, the constructed genome is relatively simplified Bac6.0-1, and the Bac6.0-2 can obviously improve the expression level of the exogenous protein.
The foregoing examples illustrate only a few embodiments of the application and are described in detail herein without thereby limiting the scope of the application. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the application, which are all within the scope of the application. Accordingly, the scope of protection of the present application is to be determined by the appended claims. All documents referred to in this disclosure are incorporated by reference herein as if each was individually incorporated by reference.
Claims (10)
1. Use of a recombinant baculovirus vector for: (a) preparing a recombinant baculovirus; or (b) inserting an exogenous gene to express the exogenous gene;
Wherein the recombinant baculovirus vector is an engineered baculovirus vector, the recombinant baculovirus vector takes a nuclear polyhedrosis virus genome sequence of the noctuid, and performs polygene deletion, including deletion Ac15、Ac16、Ac20/21、Ac22、Ac42、Ac43、Ac44、Ac55、Ac56、Ac57、Ac58/59、Ac60、Ac61、Ac69、Ac70、Ac72、Ac84、Ac85、Ac86、Ac87、Ac88 and Ac91, and deletion of genes selected from the following groups:
Ac47, ac48 and Ac49; or (b)
Ac148, ac149 and Ac150.
2. The use of claim 1, wherein in (a) the recombinant baculovirus vector is transfected into a virus-producing cell to produce the recombinant baculovirus; or (b)
(B) In (2) transfecting a virus-producing cell with a recombinant baculovirus vector inserted with a foreign gene to produce the recombinant baculovirus, which expresses a foreign protein.
3. The use according to claim 1, wherein the genomic sequence of the noctiluca californica nuclear polyhedrosis virus as a base sequence for constructing a baculovirus vector comprises the Ac1 to Ac154 genes; preferably, the alfalfa silver vein moth nuclear polyhedrosis virus genome sequence is an artificial sequence, and is from EmBacY rod grains; or (b)
Homologous recombination is carried out by utilizing lambda Red recombinase, and gene deletion is carried out; preferably, deletion of the gene is performed using the lambda Red recombinase/I-SceI enzyme traceless editing system.
4. A method of constructing a baculovirus vector comprising: the nuclear polyhedrosis virus genome of the noctuid is taken as the basis for constructing a baculovirus vector, and polygene deletion is carried out, including deletion Ac15、Ac16、Ac20/21、Ac22、Ac42、Ac43、Ac44、Ac55、Ac56、Ac57、Ac58/59、Ac60、Ac61、Ac69、Ac70、Ac72、Ac84、Ac85、Ac86、Ac87、Ac88 and Ac91, and deletion of genes selected from the following groups:
Ac47, ac48 and Ac49; or (b)
Ac148, ac149 and Ac150.
5. The method of claim 4, wherein the baculovirus vector is further provided with elements required for expression of a foreign gene; preferably, the element comprises: promoters, replicators, transposition sites, foreign gene insertion sites; optionally, the element further comprises: resistance screening markers, reporter genes;
More preferably, the promoter comprises a ph promoter, the replicon comprises a mini-F replicon, the transposition site comprises an attTn7 transposition site, the resistance selection marker comprises a kana resistance selection marker, and the reporter gene comprises an eYFP fluorescent gene.
6. A recombinant baculovirus vector which is an engineered baculovirus vector based on the genomic sequence of the noctiluca californica nuclear polyhedrosis virus and which has been subjected to polygene deletion, comprising deletion Ac15、Ac16、Ac20/21、Ac22、Ac42、Ac43、Ac44、Ac55、Ac56、Ac57、Ac58/59、Ac60、Ac61、Ac69、Ac70、Ac72、Ac84、Ac85、Ac86、Ac87、Ac88 and Ac91, and deletion of a gene selected from the group consisting of:
Ac47, ac48 and Ac49; or (b)
Ac148, ac149 and Ac150.
7. The recombinant baculovirus vector of claim 6, further comprising elements required for expression of a foreign gene; preferably, the element comprises: promoters, replicators, transposition sites, foreign gene insertion sites; optionally, the element further comprises: resistance screening markers, reporter genes;
More preferably, the promoter comprises a ph promoter, the replicon comprises a mini-F replicon, the transposition site comprises an attTn7 transposition site, the resistance selection marker comprises a kana resistance selection marker, and the reporter gene comprises an eYFP fluorescent gene;
More preferably, the alfalfa silver vein moth nuclear polyhedrosis virus genomic sequence is an artificial sequence from EmBacY bacmid.
8. A recombinant baculovirus obtained from the recombinant baculovirus vector packaging of any one of claims 6-7; or it is obtained by packaging the recombinant baculovirus vector of any one of claims 6 to 7, into which a foreign gene is inserted, which is capable of expressing a foreign protein.
9. A method of producing a recombinant baculovirus, comprising:
(A) Preparing the recombinant baculovirus vector of any one of claims 6-7;
(B) Transfecting the recombinant baculovirus vector of (a) into a virus-producing cell, thereby packaging to obtain a recombinant baculovirus;
preferably, the recombinant baculovirus vector into which the foreign gene is inserted is transfected into a virus-producing cell to produce the recombinant baculovirus, which expresses the foreign protein.
10. Use of the recombinant baculovirus of claim 8 for: expressing the exogenous gene to obtain an exogenous protein; preferably, the exogenous protein includes: immunogenic proteins, pharmaceutically active proteins, diagnostically active proteins, structural proteins, enzymes, fusion peptides, reporter proteins.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410489880.7A CN118240882A (en) | 2024-04-22 | 2024-04-22 | Multi-gene deleted high-yield baculovirus expression vector Bac6.0s and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410489880.7A CN118240882A (en) | 2024-04-22 | 2024-04-22 | Multi-gene deleted high-yield baculovirus expression vector Bac6.0s and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118240882A true CN118240882A (en) | 2024-06-25 |
Family
ID=91550876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410489880.7A Pending CN118240882A (en) | 2024-04-22 | 2024-04-22 | Multi-gene deleted high-yield baculovirus expression vector Bac6.0s and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118240882A (en) |
-
2024
- 2024-04-22 CN CN202410489880.7A patent/CN118240882A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5518913A (en) | High level recombinant protein production using conditional helper-free adenovirus vector | |
| Ketner et al. | Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. | |
| US5616326A (en) | Recombinant canine adenovirus 2 (CAV-2) | |
| US4797368A (en) | Adeno-associated virus as eukaryotic expression vector | |
| KR910009203B1 (en) | Method for rpoducing a recombinant baculovirus expression vector | |
| CA2074502C (en) | Vaccines | |
| JP3183877B2 (en) | Modified baculovirus, its preparation method and its application as expression vector | |
| Emery et al. | The development of multiple expression vectors for high level synthesis of eukaryotic proteins: expression of LCMV-N and AcNPV polyhedrin protein by a recombinant baculovirus | |
| EP0704534A2 (en) | Recombinant DNA viral vector for transfecting animal cells | |
| WO1995003400A1 (en) | Recombinationally targeted cloning in yeast artificial chromosomes | |
| JPS63301787A (en) | Hybrid rna virus | |
| EP2358883B1 (en) | Baculoviral vectors | |
| HU196238B (en) | Process for producing mature hbsag surface antigen and vaccine against hepatitis b virus | |
| AU5820790A (en) | Improved baculovirus expression vectors | |
| Mahony et al. | Construction and manipulation of an infectious clone of the bovine herpesvirus 1 genome maintained as a bacterial artificial chromosome | |
| EP0397485A1 (en) | Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells | |
| CN1237209A (en) | Herpesvirus saimiri as viral vector | |
| JPH0314840B2 (en) | ||
| CN110951778A (en) | CDV-3 strain infectious cDNA clone of canine distemper virus, construction method and application thereof | |
| Jenson et al. | Palindromic structure and polypeptide expression of 36 kilobase pairs of heterogeneous Epstein-Barr virus (P3HR-1) DNA | |
| CN113637705A (en) | Monkey type 1 adenovirus (SAdV-1) vector system and application thereof | |
| EP0143841B1 (en) | Hybrid viral plasmid and microorganisms containing same | |
| CN118240882A (en) | Multi-gene deleted high-yield baculovirus expression vector Bac6.0s and application thereof | |
| CN116042720A (en) | Transfer carrier | |
| CN114657213B (en) | Porcine acute diarrhea syndrome coronavirus artificial chromosome recombinant vector and construction method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination |